FDA Review Supports Reclassifying Marijuana as Less Risky Drug

2024-01-15
MONDAY, Jan. 15, 2024 -- Scientists from the U.S. Food and Drug Administration conclude in newly released documents that marijuana has less potential for abuse than other drugs with the same restrictions and it should be reclassified as a less dangerous drug.
Not only that, the review found there is some evidence backing its use as a medical treatment.
Right now, cannabis is classified as a Schedule I controlled substance, a high-risk category that includes heroin and LSD.
The move to reconsider the dangers of marijuana first began in 2022, when President Joe Biden asked U.S. Health and Human Services (HHS) Secretary Xavier Becerra and the attorney general to begin reviewing how marijuana is scheduled under federal law.
As part of that process, HHS Assistant Secretary for Health Adm. Rachel Levine wrote a letter to the Drug Enforcement Administration (DEA) in August supporting the reclassification of marijuana to a Schedule III drug, a list that includes ketamine, testosterone and Tylenol with codeine.
The FDA documents, which were posted online Friday, state that the agency recommends rescheduling marijuana because it meets three criteria: a lower potential for abuse than other Schedule I and II substances; an accepted medical use; and a low or moderate risk of physical dependence in people who abuse it.
The National Institute on Drug Abuse backed the recommendation, the documents state.
Although marijuana is widely used for recreational purposes, it doesn’t seem to trigger the serious outcomes that drugs such as heroin, oxycodone and cocaine do, the researchers stressed.
“This is especially notable, given the availability” of marijuana products that contain very high levels of THC, the psychoactive compound in cannabis.
The data also provides “some credible level of scientific support for some of the therapeutic uses for which marijuana is being used in clinical practice in the United States,” namely anorexia, pain, nausea and vomiting from chemotherapy, the researchers added.
Finally, the scientists noted that marijuana withdrawal has only been reported in heavy, chronic users.
And “the marijuana withdrawal syndrome appears to be relatively mild compared to the withdrawal syndrome associated with alcohol, which can include more serious symptoms such as agitation, paranoia, seizures and even death,” they added.
If the agency follows the recommendations of its researchers, rescheduling marijuana could allow for more research, give cannabis businesses the ability to bank more freely and have such firms no longer subject to a 40-year-old tax code doesn't allow credits and deductions from income generated by sales of Schedule I and II substances, CNN reported.
Twenty-four states, two territories and Washington, D.C. have legalized cannabis for adult recreational use, while 38 states allow the medical use of cannabis products, according to data from the National Conference of State Legislatures.
The DEA will have the final authority to make any changes to marijuana’s scheduling, and it will go through a process that includes a period of public comment, CNN reported.
Sources
CNN
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。